Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with pemetrexed and oxaliplatin in chemo-refractory mCRC
NCT03626922Phase 1Unknown
- Sponsor
- NSABP Foundation
- Start
- May 2019
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in colorectal cancer (metastatic) (mCRC), sponsored by NSABP Foundation. Status: unknown.
02
Drugs
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03626922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626922.